Additional studies found that SMAPs impaired tumor growth in multiple different cancer types including Burkitt’s lymphoma, pancreatic ductal adenocarcinoma, lung, and breast cancer that are driven by different oncogenes like KRAS and MYC, suggesting that PP2A reactivation may be effective for the treatment of a broad range of cancers (168, 169, 170, 171, 172). The gene discussed is MYC; the disease is cancer.